| 000 | 01697 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517112009.0 | ||
| 264 | 0 | _c20170606 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1468-330X | ||
| 024 | 7 |
_a10.1136/jnnp-2016-313772 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWijburg, Martijn T | |
| 245 | 0 | 0 |
_aMRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. _h[electronic resource] |
| 260 |
_bJournal of neurology, neurosurgery, and psychiatry _c10 2016 |
||
| 300 |
_a1138-45 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aDiagnosis, Differential |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadverse effects |
| 650 | 0 | 4 |
_aLeukoencephalopathy, Progressive Multifocal _xchemically induced |
| 650 | 0 | 4 | _aMagnetic Resonance Imaging |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdiagnostic imaging |
| 650 | 0 | 4 |
_aNatalizumab _xadverse effects |
| 650 | 0 | 4 | _aPharmacovigilance |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aWitte, Birgit I | |
| 700 | 1 | _aVennegoor, Anke | |
| 700 | 1 | _aRoosendaal, Stefan D | |
| 700 | 1 | _aSanchez, Esther | |
| 700 | 1 | _aLiu, Yaou | |
| 700 | 1 | _aMartins Jarnalo, Carine O | |
| 700 | 1 | _aUitdehaag, Bernard Mj | |
| 700 | 1 | _aBarkhof, Frederik | |
| 700 | 1 | _aKillestein, Joep | |
| 700 | 1 | _aWattjes, Mike P | |
| 773 | 0 |
_tJournal of neurology, neurosurgery, and psychiatry _gvol. 87 _gno. 10 _gp. 1138-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/jnnp-2016-313772 _zAvailable from publisher's website |
| 999 |
_c26333815 _d26333815 |
||